Patricia Inácio, PhD, science writer —

Avicanna has launched a new version of its proprietary oral cannabidiol (CBD) formulation, called RHO Phyto Micro Drop 10, in Canada. The new product will be available to certain Canadian patients, including individuals with seizures, who have medical authorization through a medical cannabis care platform, according to a…

The National Institute of Drug and Food Surveillance (INVIMA) of Colombia has approved Trunerox as an add-on treatment for seizures in people with Dravet syndrome and Lennox-Gastaut syndrome (LGS). Trunerox, which was developed by the Canadian biopharmaceutical Avicanna, is a proprietary oral formulation of 10% cannabidiol…

People with Dravet syndrome due to mutations in the SCN1A gene are more frequently affected by gastrointestinal and eating problems than those with other SCN1A-associated disorders, according to a study from the Netherlands. More than three-quarters of Dravet patients were reported to be experiencing two or more such issues, compared…

A case report from China describes a man who was diagnosed with Dravet syndrome at age 29, following an epileptic seizure that significantly worsened his walking and motor difficulties. This decline eased after one week, but “recurrent epileptic seizures contribute in some way to the development of gait and…

BL-001, an investigational oral therapy for Dravet syndrome, was well-tolerated across multiple-ascending doses in healthy volunteers, top-line data from a Phase 1 trial show. These results indicate that BL-001 can be dosed at concentrations up to 10-fold higher than the most effective dose in animal models, according to…

Baylor Genetics is offering a gene analysis service on epileptic disorders, including conditions like Dravet syndrome. The specialized panel is designed for outpatient use and is intended to assist clinicians in assessing the genetic factors underlying a patient’s epilepsy. “When a genetic cause of epilepsy is suspected, a…

Diacomit (stiripentol) was safe and clinically effective at reducing seizures when given to infants with Dravet syndrome, ages 2 or younger, according to a 30-year real world study. It also reduced emergency hospitalizations due to long-lasting seizures. “This 30-year, real-world experience shows that initiating stiripentol before the age of…

Children and adults with Dravet syndrome commonly exhibit challenging behaviors such as aggression, dangerous behavior, and impulsivity, according to a Dutch study based on responses from 20 parents. These behaviors, apart from the seizures that are a hallmark of the disease, can greatly affect the quality of life of…

A Phase 1 clinical trial that enrolled healthy volunteers to test BMB-101, Bright Minds Biosciences’ investigational treatment for Dravet syndrome, has moved to its final part, the company announced in a corporate update. This first-in-human trial of the oral therapy, which is testing BMB-101 at different doses,…

The efficacy and safety of Epidiolex, an oral cannabidiol, in children and adults with Dravet syndrome and Lennox-Gastaut syndrome (LGS) were supported in a real-world setting, with benefits similar to those seen in previous clinical trials and expanded access programs (EAPs), a Spanish EAP study reported. EAPs are…